SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

被引：0
作者：
M. Martin-Richard
R. Díaz Beveridge
V. Arrazubi
M. Alsina
M. Galan Guzmán
A. B. Custodio
C. Gómez
F. L. Muñoz
R. Pazo
F. Rivera
机构：
[1] Hospital de la Santa Creu I Sant Pau,Servicio de Oncología Médica, Medical Oncology Department
[2] Hospital Universitari I Politècnic la Fe,Medical Oncology Department
[3] Hospital de Basurto,Medical Oncology Department
[4] Hospital Vall d´Hebron,Medical Oncology Department
[5] Hospital Durán i Reynals (ICO),Medical Oncology Department
[6] Hospital Universitario la Paz,Medical Oncology Department
[7] Hospital Universitario 12 de Octubre,Medical Oncology Department
[8] Hospital Universitario Ramón y Cajal,Medical Oncology Department
[9] Hospital Universitario Miguel Servet,Medical Oncology Department
[10] Hospital Universitario Marqués de Valdecilla,undefined
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Esophageal cancer; Diagnosis; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Esophageal cancer (EC) is an aggressive tumor that represents the 6th most common cause of cancer death worldwide. The estimated incidence in Spain is 2090 cases/year. Two main pathological subtypes exist, squamous cell carcinoma and adenocarcinoma. The main differences between them are localization and underlying factors which are the principal cause of the recent incidence changes observed in west countries. Staging techniques and treatment options which combine surgery, chemotherapy and radiotherapy, reflected the high complexity of the EC management. An undeniably multidisciplinary approach is, therefore, required. In this guide, we review the status of current diagnosis and treatment, define evidence and propose recommendations.
引用
收藏
页码：1179 / 1186
页数：7
相关论文
共 180 条
  • [1] Arnal MJD(2015)Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries World J Gastroenterol 21 7933-7943
  • [2] Arenas ÁF(2014)Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma Nucl Med Commun 35 864-869
  • [3] Arbeloa ÁL(2015)The current role of staging laparoscopy in oesophagogastric cancer Ann R Coll Surg Engl 97 146-150
  • [4] Purandare NC(2010)The “best operation” for esophageal cancer? Ann Thorac Surg 89 S2163-S2167
  • [5] Pramesh CS(2001)Intensive care unit physician staffing is associated with decreased length of stay, hospital cost, and complications after esophageal resection Crit Care Med 29 753-758
  • [6] Karimundackal G(2012)Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial Lancet 379 1887-1892
  • [7] Jiwnani S(1999)Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) JAMA 281 1623-1627
  • [8] Agrawal A(2002)INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncol 20 1167-1174
  • [9] Shah S(2016)Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study Eur J Cancer 56 59-68
  • [10] Convie L(2011)Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Lancet Oncol 12 681-692
12345678910